Thymosin is a peptide, and some forms of it behave like hormones, though the full picture is more complicated than a simple yes. “Thymosin” actually refers to a family of small peptides first isolated from the thymus gland in the 1960s. The two most studied members, thymosin alpha 1 and thymosin beta 4, are structurally distinct, perform very different jobs in the body, and only one of them fits the classic definition of a hormone in the way most people understand the word. Understanding which thymosin does what clears up a lot of confusion about this group of molecules.
A Family of Peptides, Not a Single Molecule
The name “thymosin” can be misleading because it sounds like one substance. In the early 1970s, researchers at the University of Texas Medical Branch in Galveston prepared a partially purified extract from calf thymus tissue called thymosin fraction 5. That preparation turned out to contain at least 40 small, mostly acidic polypeptides with molecular weights ranging from about 1,000 to 15,000 daltons.1PubMed. History of the discovery of the thymosins Scientists gradually separated these into distinct molecules and grouped them into alpha, beta, and gamma subfamilies based on their electrical charge. As it turned out, many of these peptides were unrelated in sequence and function, lumped together only because they happened to co-purify from the same tissue. The two that attracted the most research, thymosin alpha 1 and thymosin beta 4, are essentially different molecules with different genes, different structures, and different biological roles.
Thymosin Alpha 1 and Immune Function
Thymosin alpha 1 is the member that most closely fits the description of a peptide hormone. It is a 28-amino-acid peptide first characterized from calf thymus tissue in 1977.2PubMed Central. Thymosin alpha 1: biological activities, applications and genetic engineering production In the body, it is produced by cleavage of a larger precursor protein called prothymosin alpha. A specific enzyme in lysosomes cuts prothymosin alpha at particular sites, releasing the first 28 amino acid residues as thymosin alpha 1 and the first 35 residues as a related fragment called thymosin alpha 11.3PubMed. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase
Once released, thymosin alpha 1 acts on the immune system in ways that look very much like a hormone: it is secreted, travels through the blood, and affects distant target cells. It has long been recognized for modifying, enhancing, and restoring immune function, and has been used in treating weakened immune states, cancers, and infections, as well as boosting vaccine responses and reducing illness and death from sepsis.4PubMed Central. Thymosin alpha 1: A comprehensive review of the literature A synthetic version of thymosin alpha 1 has been developed as a drug. It is rapidly absorbed after injection, reaches peak blood levels within about two hours, and clears from the bloodstream within roughly 24 hours with a half-life of around two hours. Tolerability has been good across studies, with most side effects limited to mild irritation at the injection site.5American Journal of Health-System Pharmacy. Thymosin alpha-1
So for thymosin alpha 1, the answer to “is it a peptide hormone?” is straightforwardly yes on both counts: it is a peptide, and it is secreted into the bloodstream to regulate distant immune cells, which is what hormones do.
Thymosin Beta 4 and Its Very Different Job
Thymosin beta 4, a 43-amino-acid peptide, is the other headline member of the family, and it complicates the hormone label. Unlike thymosin alpha 1, thymosin beta 4 is not primarily an immune signaling molecule. Its main known function is regulating the cell’s internal skeleton. Specifically, it binds to single units of a protein called actin and prevents those units from assembling into filaments. This makes thymosin beta 4 the principal actin-sequestering molecule in cells.6PubMed. Actin-Induced Structure in the Beta-Thymosin Family of Intrinsically Disordered Proteins Think of it as a molecular parking attendant that keeps individual actin molecules in reserve, ready to be called into service when the cell needs to move, divide, or change shape.
Structurally, thymosin beta 4 is intrinsically disordered when floating freely in solution, meaning it has no fixed three-dimensional shape. It only folds into a defined structure when it binds to actin. When bound, it wraps around the actin monomer using two helical segments that cap both the top and bottom of the actin unit, blocking it from joining a growing filament.7PubMed Central. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins 8PubMed Central. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization
Despite its name, thymosin beta 4 is not confined to the thymus. It was found decades ago in spleen tissue and immune cells called peritoneal macrophages, and it shows up across a wide range of tissues in vertebrates.9Archives of Biochemistry and Biophysics. Distribution of thymosin β4 in vertebrate classes Because thymosin beta 4 works mainly inside cells rather than being secreted into the bloodstream to signal distant targets, calling it a “hormone” in the classical sense is a stretch. It is more accurately described as an intracellular peptide that also has important effects outside cells when released during injury.
How Thymosin Beta 4 Heals Wounds
The actin-sequestering role of thymosin beta 4 turns out to have enormous implications for tissue repair. Cells that need to migrate to a wound site depend on rapid rearrangement of their actin skeleton. Thymosin beta 4 promotes angiogenesis (the growth of new blood vessels) and cell migration, and has been shown to speed wound healing in both normal and aged rodents.10PubMed. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development In the cornea, it promotes cell migration, reduces inflammation, and suppresses programmed cell death.11PubMed Central. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent
Experiments in diabetic mice, where wound healing is naturally impaired, showed that thymosin beta 4 significantly increased wound contraction and collagen deposition. In aged mice (26 months old, roughly equivalent to an elderly human), healing was markedly delayed, but thymosin beta 4 treatment accelerated it, boosting the migration of skin cells and the buildup of structural proteins. Researchers even found that a tiny synthetic fragment consisting of just seven amino acids from the actin-binding region of thymosin beta 4 could reproduce much of the wound-healing effect of the full molecule.12PubMed. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice This finding was important because smaller peptides are generally cheaper and easier to manufacture.
Animal studies across multiple disease models have provided the groundwork for clinical trials in skin, corneal, and cardiac wound repair. The molecule’s biological activities are broad: it dampens inflammatory signaling molecules, encourages new blood vessel formation, promotes cell survival, and supports the maturation of stem cells.13PubMed. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide The breadth of these effects and the clinical potential for repairing ulcerated tissues and damaged organs after events like heart attacks and strokes has made thymosin beta 4 a molecule of intense interest.14Trends in Molecular Medicine. Biochemical and molecular properties of thymosin β4 and its role in tissue repair
Cardiovascular Regeneration After Heart Attacks
One of the most striking findings in thymosin beta 4 research involves the heart. In mouse models of heart attack, thymosin beta 4 was described as the first known molecule able to simultaneously trigger both muscle and blood vessel regeneration in the heart after being given systemically. It inhibited heart muscle cell death, stimulated the growth of new vessels, and activated dormant cardiac progenitor cells by essentially reminding the adult heart of developmental programs it used during embryonic growth.15PubMed. Thymosin beta4 and cardiac repair
Follow-up research explored combining thymosin beta 4 with cardiac reprogramming approaches, suggesting the two strategies could work together to limit damage and promote regeneration through cells already present in the heart.16PubMed. Cardiac repair with thymosin β4 and cardiac reprogramming factors In another mouse study, five weeks of thymosin beta 4 treatment after a heart attack reduced a deadly complication called cardiac rupture, improved overall heart function, reduced scar tissue formation, and increased the density of small blood vessels in the damaged area.17PubMed Central. Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction These results remain preclinical, meaning they have been demonstrated in animals but not yet proven in large human trials, so it is worth keeping expectations measured. Still, the cardiac data is some of the most compelling evidence that thymosin beta 4 does far more than manage actin inside cells.
Cell Migration Is a Double-Edged Sword
Any molecule that promotes cell movement and tissue remodeling inevitably raises questions about cancer. Cancer cells co-opt many of the same migration and growth mechanisms that normal wound healing uses, so it would be surprising if thymosins had no connection to tumor biology. And indeed, the connection runs in both directions: some thymosins appear to promote tumor progression, while thymosin alpha 1 has been explored as a cancer treatment.
Experiments altering thymosin beta 4 levels inside cells showed the trade-off clearly. When researchers increased thymosin beta 4 in cultured cells, actin filament bundles shrank and cell migration dropped. When they knocked thymosin beta 4 down, actin networks expanded and cells migrated faster.18PubMed. Thymosin beta4 inhibits ADF/cofilin stimulated F-actin cycling and hela cell migration: reversal by active Arp2/3 complex The picture in living tumors, however, is not that simple. In colorectal cancer patients, high thymosin beta 4 levels in tumor tissue were linked to more lymphovascular invasion, more lymph node spread, deeper invasion, and more advanced tumor stage, and predicted worse outcomes.19PubMed Central. Increased Expression of Thymosin β 4 Is Independently Correlated with Hypoxia Inducible Factor-1α (HIF-1α) and Worse Clinical Outcome in Human Colorectal Cancer
On the treatment side, thymosin alpha 1 has been tested as part of combination therapies for liver cancer. In one study of patients with unresectable hepatocellular carcinoma, adding thymosin alpha 1 to a regimen of two other drugs extended median overall survival from 11 months to 16 months and progression-free survival from 4 months to 7 months, with response rates roughly 20 percentage points higher in the thymosin group and no significant increase in serious side effects.20Scientific Reports. The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study This was a retrospective study with fewer than 100 patients, so it is far from definitive, but it adds to a body of evidence suggesting thymosin alpha 1 can meaningfully boost anti-cancer immune responses when paired with other treatments.
Other Thymosin Family Members and Cancer Biomarkers
Thymosin alpha 1 and beta 4 get most of the attention, but the family has other members with their own biological stories. Thymosin beta 10, for instance, has been found to promote proliferation, invasion, and migration of breast cancer cells through a specific signaling pathway, and overexpression of thymosin beta 10 in breast tissue is being investigated as both a driver of tumor growth and a potential blood-based biomarker.21PubMed Central. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer In colorectal cancer, thymosin beta 10 protein levels in tumor tissue were higher than in neighboring normal tissue, and blood levels in cancer patients were significantly elevated compared to healthy people, raising the possibility of a minimally invasive blood test for detecting the disease.22Translational Oncology. Can thymosin beta 10 function both as a non-invasive biomarker and chemotherapeutic target in human colorectal cancer?
Thymosin beta 15, another family member, has a specific isoform whose knockdown suppressed migration of prostate cancer cells, suggesting a functional role in tumor spread.23PubMed Central. Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1 A thymosin beta 4-like protein has also been flagged as a potential blood biomarker for gastric cancer.24PubMed. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer The pattern across these studies is consistent: because thymosins help control cell movement and growth, their levels tend to be abnormal in cancers, making them useful as indicators even when they are not necessarily the cause.
Thymic Involution and Why Thymosin Declines With Age
The thymus gland, where thymosin alpha 1 is most concentrated, does not stay the same size throughout life. It is largest during childhood and begins shrinking, a process called involution, surprisingly early. Blood levels of thymosin alpha 1 start declining as early as age 10, and a related thymic hormone called FTS disappears from the blood entirely between the fifth and sixth decade of life.25PubMed. Involution of the mammalian thymus, one of the leading regulators of aging Circulating thymic hormone activity is highest between the ages of 15 and 30, after which it gradually drops off, becoming negligible after about age 60. This decline tracks closely with the physical shrinkage of the thymus itself.26The Journal of Clinical Endocrinology & Metabolism. Age, Thymic Involution, and Circulating Thymic Hormone Activity
This age-related decline in thymic peptides is one reason older adults have weaker immune responses and respond less robustly to vaccines. It is also part of the rationale for giving synthetic thymosin alpha 1 to elderly or immunocompromised patients: replacing what the aging thymus no longer produces in sufficient quantities. Whether supplementing thymosin alpha 1 can meaningfully reverse broader aspects of immune aging remains an open and actively studied question.
TB-500, Doping, and the Gray Market
If you have heard of thymosin beta 4 outside a medical context, it was probably under the name TB-500. This is a product sold online and in some veterinary settings that contains a fragment of the thymosin beta 4 sequence. It has attracted attention among athletes and in equine racing because of its wound-healing and tissue-repair properties. The formulation is suspected to be used as a doping agent in sport.27PubMed. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
TB-500 is not an approved drug for human use in most countries. Products sold under this name are unregulated, meaning their purity, dose, and actual contents are not verified by any health authority. The legitimate science on thymosin beta 4 comes from controlled laboratory and animal studies, and from early-stage clinical trials. Buying TB-500 from an internet peptide vendor and injecting it is a very different situation from receiving a pharmaceutical-grade product in a clinical trial, and the risks of contamination, misdosing, or outright fraud are real. Thymosin beta 4 speeds dermal healing across multiple preclinical models, including in diabetic and aged animals and in burn injuries.28PubMed. Thymosin β4 Promotes Dermal Healing But the gap between “works in mice” and “safe for self-administration by a person who bought it online” is enormous.
An Ancient Molecule Conserved Across Animal Life
One reason researchers take thymosin beta 4 so seriously is how far back in evolutionary history it reaches. The beta-thymosin domain probably first appeared in a single-celled organism closely related to the ancestor of all multicellular animals. From there, gene duplications expanded the family so that present-day jawed vertebrates carry descendants of at least five ancestral beta-thymosin genes.29PubMed. Single-domain β-thymosins: the family history Beta-thymosin-like proteins have been found in organisms as distantly related to humans as disk abalone, a type of sea snail, where phylogenetic analysis confirmed a shared ancestral origin with other mollusk versions of the protein.30PubMed. Structural characterization and expression analysis of a beta-thymosin homologue (Tβ) in disk abalone, Haliotis discus discus
The evolutionary distribution is not perfectly uniform, though. Comparison of beta-thymosin sequences across the animal kingdom revealed that arthropods and nematodes (insects, crustaceans, and roundworms) lack the highly conserved form of beta-thymosin found in nearly all other animal groups, including sponges. Instead, arthropods and nematodes share an unusual, internally triplicated version of the protein not found in other animal lineages.31PubMed. The comparison of beta-thymosin homologues among metazoa supports an arthropod-nematode clade This molecular quirk has actually been cited as evidence supporting the grouping of arthropods and nematodes together on the tree of life, an example of how a small peptide can inform big questions in evolutionary biology. The deep conservation of beta-thymosins underscores that actin regulation is so fundamental to cell function that organisms have maintained these molecules across hundreds of millions of years of evolution.